Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
12:36pm, Thursday, 06'th Jun 2024
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
06:30am, Thursday, 30'th May 2024
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gius
National Bank of Canada FI Grows Position in Beam Therapeutics Inc. (NASDAQ:BEAM)
05:06am, Monday, 20'th May 2024
National Bank of Canada FI boosted its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 200.0% during the 4th quarter, according to the company in its most recent disc
DESERT MOUNTAIN ENERGY ANNOUNCES STRATEGIC PARTNERSHIP WITH BEAM EARTH LTD. FOR HYDROGEN IN ARIZONA AND NEW MEXICO
08:30am, Thursday, 16'th May 2024
TSX.V: DMEU.S. OTC: DMEHF Frankfurt: QM01 VANCOUVER, BC , May 16, 2024 /PRNewswire/ - DESERT MOUNTAIN ENERGY CORP. (the "Company") (TSXV: DME) (U.S. OTC: DMEHF) (Frankfurt: QM01) From the President of
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
06:49am, Thursday, 09'th May 2024
Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and t
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
11:56am, Wednesday, 08'th May 2024
Beam Therapeutics (BEAM) reports mixed first-quarter results. The company remains focused on pipeline development.
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
06:30am, Wednesday, 08'th May 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
06:30am, Tuesday, 07'th May 2024
Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Wednesday, 01'st May 2024
Beam Therapeutics (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
12:36pm, Thursday, 28'th Mar 2024
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
06:19am, Wednesday, 06'th Mar 2024
Beam Therapeutics Inc. NASDAQ: BEAM is a biotech company that specializes in developing precision gene therapies for hereditary diseases. The medical sector company is a pioneer in a proprietary gene-
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
06:30am, Wednesday, 28'th Feb 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
06:30am, Tuesday, 27'th Feb 2024
Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024
